Evidence map›Paper›PMID 42708224›Full record

ArticleCirculation2026

Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in

Mustafa Yalcinkaya, Cheng-Chieh Hsu, Linke Li, Ranran Wang, David Ngai, Pablo Sánchez Vela, Ines Fernandez-Maestre, Malgorzata Olszewska, Wenli Liu, Miao Chen and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mustafa YalcinkayaDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).ORCID 0000-0003-2199-0886
Cheng-Chieh HsuDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).
Linke LiCenter for Genomic Medicine, Massachusetts General Hospital, Boston (L.L., Z.Y.).
Ranran WangDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).ORCID 0000-0001-6846-4483
David NgaiDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).ORCID 0000-0002-9576-5254
Pablo Sánchez VelaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY (P.S.V., I.F.-M., R.L.).ORCID 0000-0002-9286-8290
Ines Fernandez-MaestreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY (P.S.V., I.F.-M., R.L.).
Malgorzata OlszewskaDepartment of Oncological Sciences (M.O., E.P.P.), Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0009-0004-3416-1635
Wenli LiuDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).ORCID 0000-0002-1981-611X
Miao ChenDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).
Sandra SchiavoneDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).
Tong XiaoDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).ORCID 0000-0003-1462-4650
Eirini P PapapetrouDepartment of Oncological Sciences (M.O., E.P.P.), Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0001-7002-417X
Nan WangDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).ORCID 0000-0001-9976-0859
Ross LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY (P.S.V., I.F.-M., R.L.).ORCID 0000-0002-7884-1905
Zhi YuCenter for Genomic Medicine, Massachusetts General Hospital, Boston (L.L., Z.Y.).ORCID 0000-0003-4810-3474
Ira TabasDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).ORCID 0000-0003-3429-1515
Alan R TallDepartment of Medicine, Irving Medical Center, Columbia University, New York, NY (M.Y., C.-C.H., R.W., D.N., W.L., M.C., S.S., T.X., N.W., I.T., A.R.T.).ORCID 0000-0002-7708-2417

Funding

Mouse and Human Atherosclerotic TissueP01HL172741 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALAN richard TALL · 2024 to 2026
$9.5M
Cholesterol efflux, CHIP and inflammasome activationR01HL107653 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALAN richard TALL · 2011 to 2026
$7.7M
Clonal hematopoiesis, inflammasomes and atherosclerosisR01HL155431 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALAN richard TALL · 2021 to 2026
$3.7M
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutationsR01CA271331 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2022 to 2026
$3.3M
Impact of mutational order on molecular mechanisms of oncogenesisR01CA260711 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2022 to 2026
$3.2M
Multi-omic dissection of clonal hematopoiesis-associated diseasesR00HG012956 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI Zhi Yu · 2024 to 2026
$747k
American Heart Association-American Stroke Association 24CDA1275172NCI NIH HHS R01 CA260711NCI NIH HHS R01 CA271331NHGRI NIH HHS R00 HG012956NHLBI NIH HHS P01 HL172741NHLBI NIH HHS R01 HL107653NHLBI NIH HHS R01 HL155431
6 · The paper itself

Abstract

backgroundClonal hematopoiesis (CH) arising from mutations in hematopoietic genes has been identified as an important risk factor for atherosclerotic cardiovascular disease. Despite the established role of some CH mutations in promoting atherosclerosis progression, their role in clinically relevant LDL (low-density lipoprotein) lowering-induced plaque remodeling or regression has not been extensively studied.

methodsTo assess the effects of TET2 (tet methylcytosine dioxygenase 2) CH on plaque resolution, we prepared control or chimeric

resultsUnlike control mice,

conclusionsOur data identify impaired efferocytosis and glycolysis-lactate-actin polymerization pathways in advanced atherosclerosis as potential therapeutic targets to induce proresolving restructuring of the plaque immune cells and to promote beneficial atherosclerosis remodeling in subjects with

Indexed as

actin polymerizationatherosclerosisclonal hematopoiesisefferocytosisglycolysisLDL loweringTrem2hi macrophages

Identifiers

PMID42708224
PMCPMC13556357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.